NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

MapLight Therapeutics, Inc. (MPLT) Stock Analysis

MapLight Therapeutics, Inc. (MPLT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MPLT

$13.77

+$0.63 (+4.79%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MPLT with… →

MPLT Key Statistics

As of Sep 4, 2026
Trading
Open
$13.03
Previous Close
$13.14
Day's Range
13.00–14.14
52-Week Range
9.10–40.43
Volume
550.90K
Valuation
Market Cap
$638.62M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−19.96
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$161.15M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
43.65M
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
865.20K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MPLT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−21.61%
2025 (partial year)−4.23%

As of September 4, 2026.

MPLT Valuation vs Biotechnology Median

Median of 656 stocks
MetricMPLTBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

MapLight Therapeutics, Inc. (MPLT) is capitalised at $638.62M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 133.

The most recent close on file for MPLT is $13.77, dated September 4, 2026. That is +$0.63 (+4.79%) against the previous close. The 52-week range on file runs from $9.10 to $40.43. The latest close sits 51.32% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $161.15M. The reported profit margin is 0%. Trailing earnings per share are −19.96.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The stored price history starts on October 27, 2025, and the total return since then is −24.92%.

Growth & Income

The record shows no dividend for MPLT.

So far in 2026 the price is −21.61%.

Peer Comparison

MapLight Therapeutics, Inc. (MPLT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MapLight Therapeutics, Inc. MPLT $638.62M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. MapLight Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.

Visit website →